Anti-Le a monoclonal antibody SPM 522 recognizes an extended Le a epitope
Insights into the differential binding characteristics of anti-Le and anti-Le Le monoclonal antibodies (mAbs) provide information to develop Le Le -based cancer immunotherapeutics while avoiding anti-Le autoimmune reactions. We characterized the epitope recognized by anti-Le mAb SPM 522. We synthesi...
Saved in:
Published in | Bioorganic & medicinal chemistry Vol. 56; p. 116628 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
15.02.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Insights into the differential binding characteristics of anti-Le
and anti-Le
Le
monoclonal antibodies (mAbs) provide information to develop Le
Le
-based cancer immunotherapeutics while avoiding anti-Le
autoimmune reactions. We characterized the epitope recognized by anti-Le
mAb SPM 522. We synthesized the Le
6-aminohexyl glycoside and report experimental evidence of a minor conformation in solution. The Le
and three other 6-aminohexyl glycosides were conjugated to BSA and titration experiments with SPM 522 show that: 1. SPM 522 binds to Le
Le
better than to Le
; 2. the non-reducing Le
galactosyl residue is essential to binding. Competitive ELISA experiments using a panel of tri- to pentasaccharide fragments of Le
Le
as well as Le
analogues indicate that: 1. the Le
β-d-galactosyl α hydrophobic patch is crucial to binding; 2. the Le
fucosyl residue contributes to binding; 3. the Le
d-galactosyl residue also contributes to binding. These results indicate that anti-Le
mAb SPM 522 recognizes the Le
[1,3]-β-d-Gal tetrasaccharide. We propose that a major recognition element is the extended hydrophobic surface defined by the Le
-β-d-Gal residue extending to the α faces of the β-d-GlcNAc and β-d-Gal residues. |
---|---|
ISSN: | 1464-3391 |
DOI: | 10.1016/j.bmc.2022.116628 |